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Abstract 
ABC drug efflux transporters are transmembrane proteins which are known to play a 
crucial role in drug resistance. The ability of these proteins to actively transport a wide variety of 
compounds out of the cell is one of the key reasons behind the resistance of cancer cells to 
chemotherapeutic agents. To study the activity of efflux transporters and identify their substrates 
or inhibitors a number of in vitro models have been developed. These models are based on the 
mammalian cells genetically modified in order to express the protein of interest. For genetic 
manipulations of the cells various expression plasmids are used. In our study we attempted to 
prepare a universal expression plasmid, containing a short sequence of V5 tag. Such plasmid 
enables further cloning of coding sequences of selected efflux transporters so that the V5 tag is 
localized on their 3’-end. Once constructed, the plasmid can further be used to transfect the 
desired cell line, thus developing an in vitro cell model. Since the transporter is produced as a 
fusion protein with the V5 tag localized on their C-end, the tag could be used as a universal 
marker of the transporter expression detectable by immunohistochemical methods. To construct 
the V5 tag sequence two approaches were employed both leading to the product of the desired 
sequence of V5 tag DNA.  This sequence was further cloned into the selected plasmids: 
expression plasmid pZeoSV2(-) and retroviral plasmid pLNCX2. Only the cloning of V5 tag into 
pLNCX2 was successful in producing the universal expression plasmid pLNCXV5, prepared for 
insertion of cDNA of selected transporter.  
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ABC jsou velká skupina transmembránových proteinů, o kterých je známo že hrají 
klíčovou roli v rozvoji lékové rezistence. Schopnost těchto proteinů aktivně transportovat 
širokou škálu látek ven z buňky je hlavním principem – schopnosti řady nádorových buněk 
odolávat působení chemoterapeutik. Pro studium aktivity lékových transportérů a jejich substrátů 
či inhibitorů bylo vyvinuto množství in vitro modelů. Tyto modely jsou založeny na využití 
savčích buněk, které jsou geneticky manipulovány tak, aby v plazmatické membráně 
exprimovaly vybraný efluxní transportér. Pro genetické modifikace těchto buněk se využívá řada 
produkčních plazmidů. V naší práci jsme se zaměřili na vývoj univerzálního produkčního 
plazmidu obsahujícího krátkou V5 tag sekvenci a umožňujícího následné vklonování kódující 
sekvence vybraného lékového transportéru tak, aby byl V5 tag lokalizován na jeho 3’ konci. 
Výsledný produkční plazmid tak může být dále použit k transfekci vhodné savčí buněčné linie, 
která bude sloužit jako model pro studium aktivity efluxního transportéru in vitro. Vybraný 
transportér je v buněčné linii produkován jako fúzní protein s V5 tagem lokalizovaným na jeho 
C-konci. Tak může tento tag sloužit jako univerzální marker proteinové exprese detekovatelný s 
pomocí imunohistochemických metod. Pro konstrukci V5 tagu jsme použili dva přístupy 
skládání oligonukleotidů. Oba tyto přístupy se nakonec ukázaly jako vhodné. Sekvence V5 tagu 
byla po izolaci vklonována do vybraných plazmidů: expresní plazmid pZeoSV2(-) a retrovirový 
plazmid pLNCX2. Klonování V5 tagu se podařilo pouze v případě pLNCX2. Vzniklý 
univerzální plazmid pLNCXV5 je tak připraven pro vklonování kódující sekvence vybraného 
lékového transportéru. 
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1. Abbreviations: 
ABC Transporters - ATP-binding cassette transporters  
DNA - Deoxyribonucleic Acid 
RNA – Ribonucleic Acid 
mRNA – Messenger Ribonucleic Acid 
CFTR - Cystic Fibrosis Transmembrane Receptor 
BCRP – Breast Cancer Resistant Protein 
MRP – Multidrug (Associated) Resistant Protein  
TMD - Transmembrane Domains 
NBD - Nucleotide Binding Domains 
ICLs - Intracellular Loops 
ATP - Adenosine triphosphate 
ADP - Adenosine diphosphate 
MDR- Multi Drug Resistance 
TR(-) – Mutant Rat of MRP2 
P-gp - P-glycoprotein 
CF-1 mouse – P-glycoprotein mutant mouse 
MDCK – Madin-Darcy canine kidney cell line 
SV5 - simian virus 5 
UV – Ultraviolet light 
TBE - Tris-borate buffer 
SOC medium - Super Optimal broth with Catabolite repression medium  
PCR – Polymerase Chain Reaction 
RT-PCR – Real Time Polymerase Chain Reaction 
Pi - Phosphate 
bp – base pair 
LB - Lysogeny Broth 
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2.  Introduction 
 ATP binding cassette transporters (ABC transporters) are a large group of transmembrane 
proteins that utilize energy of ATP hydrolysis to transport various substrates across the cell 
membrane, into or out of the cell. They transport ligands across the cellular lipid membranes, 
which are critical for most aspects of cell physiology including the uptake of nutrients, 
elimination of waste products, energy generation and cell signaling1. There are many different 
transporters, in both eukaryotes and prokaryotes, which are important for cells function and 
survival. ABC transporters are just one of these vast transporters crucial for cells survival. Their 
three most known functions are import, export and maintenance and repair of DNA2. However, 
in prokaryotes there are importers and exporters. The importers functions to transport nutrients 
into the cell across the membrane. These nutrients include sugars, amino acids, peptides, 
phosphate esters, inorganic phosphate, sulfate, phosphonates, metal cations, iron-chelator 
complexes, vitamins, and polyamines3. On the contrary, eukaryotes only have exporters1. Their 
function is to remove compounds such as drug or toxins that are found in the cell1. Some ABC 
transporters, located in the cytosol, are also involved in processes of maintaining and repairing 
DNA, and mRNA translation2. 
 A large subgroup of ABC transporters called drug efflux transporters have recently been 
identified in mammals. These proteins act solely as effluxers and are able to transport a vast 
number of chemically distinct molecules out of the cell. They are expressed throughout the body 
especially in the plasma membrane of the intestine, kidney and liver epithelia and in 
physiological barriers (blood-brain, hemato-testicular, placental)4. In these tissues they affect 
absorption, distribution and elimination of their substrates, including drugs. Thus, modulating 
their therapeutic efficiency. Furthermore, the over-expression of some efflux transporters in 
cancer cells has been related to the phenomenon of multidrug resistance5. As these transporters 
can fundamentally affect drug efficacy, profound investigation of the potential interaction with 
efflux transporters is very important especially in the discovery of new therapeutic agents and 
their development. 
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 3.1 ABC Transporters of Prokaryotes 
 Prokaryotic ABC transporters are responsible for the cells viability, virulence and 
pathogenicity6. There are many different ABC transporters in prokaryotes, each having its own 
special function and a role in the organism’s survival. Hence, their dysfunction could lead to 
severe consequences leading to serious effects on the organism. Prokaryotes have both importers 
and exporters, which transport nutrients into the cell and toxins out of the cell for its viability5. 
They are predominantly unidirectional making their main function as importers of compounds 
that cannot be obtained by diffusion (sugars, vitamins, metal, ions, etc.) into the cell6. Other 
transporters are solely devoted to exporting virulence factors in suitable conditions. An example 
is iron ABC uptake systems, which have long been recognized as important effectors of 
virulence6. These pathogens obtain iron by releasing siderophores which have high affinity 
towards iron complexing molecules and once the iron siderophore complex is formed it is 
reabsorbed6. The iron complexing molecules, biologically available in the body, is found 
chelated by high-affinity iron-binding proteins (BPs) (e.g., transferrins, lactoferrins, and ferritins) 
or as a component of erythrocytes (such as heme, hemoglobin, or hemopexin)6.  
Another example of virulence is through the expression of virulence genes in 
Agrobacterium tumefaciens7. The virulence gene ChvE codes galactose and glucose importers. 
Once the sugar binds to regulatory region of ChvE gene it results in a response that expresses the 
virulence gene7. Prokaryotic ABC transporters are also responsible in maintaining homeostasis in 
the cell, which is very crucial in cells vitality6. An example of homeostasis is the osmosensing 
ABC transporters that mediate uptake of compatible solutes, which are activated once there is an 
increase in osmotic strength6.  
 
3.2 ABC Transporters of Eukaryotes 
 The main difference between eukaryotes and prokaryotes is that eukaryotes lack 
importers, therefore only have exporters. They are responsible for transporting toxins absorbed 
from the environment as well as metabolic by-products out of the cell1. Since they are one of 
many transmembrane proteins responsible for cells ability to function properly, their 
polymorphism may have a big impact on the organism. There are approximately 50 known ABC 
transporters in the human body. Currently, there are 13 known genetic diseases as a result of 
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their polymorphisms8. The most common genetic diseases include; cystic fibrosis, Stargardt 
disease, age related macular degeneration, adrenoleukodystrophy, Tangier disease, Dubin-
Johnson syndrome and progressive familial intrahepatic cholestasis8. Certain ABC transporters 
responsible for these genetic disorders do not function by moving substrates across the 
membrane instead they control the ion channels8, for example cystic fibrosis transmembrane 
receptor (CFTR). Polymorphism of ABCC7 (CFTR) leads to its dysfunction and acquirement of 
cystic fibrosis8. Summary of genetic disorders and the responsible transporters is seen in Table 1, 
below. 
 
Table 1: Summary of human diseases associated with specific ABC transporters 8.This figure 
was obtained Gottesman MM and Ambudkar SV, 2001. 
 
 
 
The normal function of some ABC transporters is to excrete cytotoxic compounds, such 
as dietary cytotoxics as well as therapeutic agents, from the cell. As mentioned previously the 
group so called drug efflux ABC transporters are associated with altered drug bioavailability and 
drug resistance. Among the most important drug efflux transporters in humans are: P-
glycoprotein (P-gp, ABCB1, MDR1), Multidrug Resistance Associated Proteins 1-5 (MRP1-
MRP5, ABCC1-ABCC5) and Breast Cancer Resistant Protein (BCRP, ABCG2)4. They are 
highly expressed in gut, liver and kidneys where they restrict the bioavailability of the 
administered drugs4. P-gp and BCRP are also expressed in the epithelia of sensitive tissue, for 
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example the brain, as well as in stem cells where they perform a barrier function4. Therefore, 
these transporters complicate the delivery process of therapeutic agents to the diseased cells. 
Another problem lies in the over-expression of ABC transporters in plasma membrane of cancer 
cells. Enhanced expression of the transporter results in enhanced efflux and decreased effective 
concentrations of the chemotherapeutic agent in the cell, leading to drug resistance. An example 
of this is the P-gp which is over-expressed in chemotherapy-resistant tumors, such as colon and 
kidney cancers, and is up-regulated after disease progression following chemotherapy in 
malignancies such as leukemia and breast cancer9. This topic will be covered further in detail 
later in the thesis. 
On the contrary, expression of efflux transporters can also be beneficial, as is the case in 
pregnant women. Placenta plays a crucial role in delivering nutrients and exchanging waste 
between the fetus and the mother. There is evidence which demonstrates that the placenta 
expresses a large number of transporters, such as; P-gp, MRP1, MRP2, MRP3 and BCRP10. This 
indicates that ABC transporters, which cause drug resistance, may also serve as a protective 
mechanism of the fetus, preventing the transport of endogenous compounds and xenobiotics to 
the fetus10. Thus preventing any harm being done during its development.  
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4. Structure 
 To have a better understanding of function and mechanism of ABC transporters, we first 
need to have a good knowledge of their structure. In general all ABC transporters contain a core 
structure of two transmembrane domains (TMD) and two nucleotide binding domains (NBD)11 
(Figure 1). 
 
 
Figure 1: This is a general structure of an ABC transporter with two TMDs as well as two 
NBDs1. The two TMDs are located in the cell membrane with the NBDs attached to them1. This 
figure was obtained from Linton KJ, 2007. 
 
The TMD is composed of 6-12 membrane spanning alpha helices and contain the specific 
substrate binding sites11. One of the most striking properties of ABC transporters is their ability 
to recognize and transport a vast variety of substrates of diverse chemical structure due to their 
variability in sequence and structure11. The two TMDs consist of hydrophobic segments, which 
span the membrane and form a transmembrane channel that allows nutrients or toxins to flow 
through8. While NBD are more organized with less variability in their structure. They contain 
characteristic motifs (Walker A and B), separated by approximately 90-120 amino acids, found 
in all ATP-binding proteins11. NBDs also contain an additional element, the signature (C) motif 
also known as LSGGQ motif, located just upstream of the Walker B11, which is the diagnostic 
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sequence of ABC proteins12 (Figure 2). Unlike TMD the NBD of ABC transporter is found in the 
cytosol where the ATP binding site is located11. 
  
 
 
 
 
Figure 2: A picture of NBD dimer and conserved motifs1. Figure A: ABC transporter with 
closed NBD dimers (gold-blue and lighter gold-blue color), with two ATPs at the dimer 
interface1. Figure B: ATP is elementally colored and surrounded by Walker A and B motifs, the 
H-loop, stacking aromatic, and Q-loop of the core subdomain1. Q-loop extends from the top 
surface of the NBD, where it is close proximity to the ICLs of the TMDs, allowing the Q-loop to 
transduce signals and energy within the complex1. This figure was obtained from Linton KJ, 
2007. 
 
 
In order to become functional the transporters structure needs to be fully formed, 
consisting of four polypeptide chains, with the core structure being a C-terminal NBD connected 
to N-terminal TMD12, together forming four component single polypeptide chain, NBD-TMD-
NBD-TMD12. This is the usual sequence for the eukaryotic transporters found in for example P-
gp. There are also exceptions to the polypeptide chain, with the most usual of these being half-
transporters (eg. BCRP)12. However, these half transporters must also form either homodimers or 
heterodimers to form a fully functional transporter11. Another exception is the structure of some 
MRP transporter (MRP 1-3) where three instead of two TMD and two NBD pile up to form 
functional transmembrane protein, (refer to figure 3)13. 
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Figure 3: Comparison of alternate structures of ABC transporters13. Figure A: shows P-gp with 
two TMDs (with six transmembrane segments) and two NBDs, with the N-glycosylation on the 
first extracellular loop13. Figure B: MRP 1-3 have the same general structure as P-gp, but contain 
an additional aminoterminal extension with 5 transmembrane segments  and are also N-
glycosylated near the N-terminus and at the sixth extracellular loop13. Figure C: MRP 4-5 do not 
have the extra 5 transmembrane segment and are also N-glycosylated on the fourth extracellular 
loop13. Figure D: BCRP on the other hand is a half transporter containing only one NBD and a 6 
transmembrane segments, with the N-glycosylation occurring on the third extracellular loop13. 
This figure was obtained from Schinkel A. and Jonker J., 2003. 
  
   
From previous research we can see that the structure of ABC transporters, like the P-gp, 
has been examined through electron microscopy and electron cryomicroscopy showing that 
TMDs form an aqueous chamber4. The TMDs appear to be open at the extracellular face but 
closed intracellularly, with the two NBDs exposed as cytoplasmic lobes4. ABC transporters also 
contain the loops Q, D and H, which are found in the NBDs and play an important role in their 
function. The Q loop is a glutamine residue, which connects TMD and NBD, and is responsible 
for interaction between the two. The importance of the Q loop is due to its position in the 
transporter which allows it to couple the ligand binding sites within the TMDs to the ATP 
binding sites of the NBDs1. This allows a conformational change of TMDs during ATP 
15 
 
hydrolysis, resulting in translocation of the ligand (substrate). The H loop, which is the histidine 
residue, also contributes to the translocation through its interaction with ATP in the NBD1.  
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5. Mechanism of Action 
 The four ABC transporter domains work explicitly together to translocate substrates 
through the cell membrane. This process involves communication via conformational changes, in 
both directions, between the NBDs and TMDs4. Since most of the focus is on the multi drug 
resistance proteins, the P-gp will serve to explain the mechanism of action. It is a four step 
mechanism, which cycles between high and low affinity states for ligands on different side of the 
membranes1. Additionally, it is known as the on-off switch where the NBDs conformational 
changes serve as the drive for transport4. NBDs closed dimer, one of the conformations, is 
formed when the two ATP molecules bind at its interface4. The other conformation, or the open 
dimer, results after ATP is hydrolyzed and ADP together with phosphate (Pi) are released 
allowing NBDs to open4. Each switch in the NBDs induces a conformational change in the 
TMDs, which is required for the translocation of the ligand8. For a better understanding refer to 
Figure 4 below. 
 
 
Figure 4: ABC transporters mechanism can be categorised into a four steps involved in the 
transportation of a substrate out of the cell. First the substrate binds to its high affinity site on 
TMDs, as a result conformational change occurs in the transporter. This change increases affinity 
towards ATP on the NBDs. Once ATP is bound it causes NBDs to close, which induce another 
conformational change in the TMDs. This allows TMDs substrate sites to change to low affinity 
and release the substrate. Once the ATP is hydrolysed and released in the form of ADP and Pi, 
the molecule returns to its resting state. This figure was obtained from Linton KJ, 2007. 
 
First Step: 
The ABC transporter is in basal state, meaning that the NBDs are in an open 
conformational state with a low affinity towards ATP, while the TMDs are in a high affinity state 
towards the ligands and are easily accessible from the cytoplasm of the cell membrane1. Once the 
ligand binds to its high affinity site on the TMDs it initiates the four step mechanism, or the 
translocation cycle, where the binding of the substrate initiates a conformational change in the 
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transporter1. The conformational change results in an increased affinity towards ATP on the 
NBDs1. The evidence to support this has been demonstrated from structural studies of HlyB and 
LolD that have concluded that the conformational change is transduced via intracellular loops 
(ICLs) of the TMDs, and the close proximity of ICLs to the Q loop and Walker A motif suggests 
that the binding of the substrate can directly influence the NBDs affinity towards ATP1.   
 
Second Step: 
Once ATP has bound to its high affinity site on the NBDs, it causes the NBDs to change 
from opened dimer to a closed dimer around the bound ATP molecules1. This change in NBDs 
dimer induces a major conformational change in the TMDs to initiate substrate translocation4. 
The conformational adjustment allows the TMDs high affinity site, accessible in the cytoplasm, 
to change into low affinity site allowing the substrate to leave the transporter on the extracellular 
face of the membrane1. Because it is an active transporter, which requires energy to induce 
conformational changes, it was hypothesised that the energy produced by ATP hydrolysis was 
responsible for the conformational changes1. Recent research have concluded that ATP binding 
and formation of the NBDs closed dimer, and not the hydrolysis, generates a significant amount 
of energy to induce key conformational changes of the TMDs involved in substrate transport1. 
The extent of this conformational change is large and can be visualised directly for P-gp at a low 
resolution1. 
 
Third Step: 
  ATP is hydrolysed to initiate transition of NBDs from a closed dimer to an open dimer1. 
The hydrolysis destabilises the closed dimer to initiate the resettling of the transporter to its basal 
state1. The process of ATP hydrolysis initiation is still not fully known. However, two theories 
exist. The first theory postulates that once the substrate is released from the TMDs, it triggers a 
conformational change which is transmitted to the NBDs initiating the hydrolysis1. The second, 
more likely theory of the two, indicates that ATP hydrolysis is an automatic process upon the 
closure of the NBDs1. For certain ABC transporters like the P-gp, hydrolysis of both ATPs is 
required for completion of the transport cycle, and these two ATP molecules are hydrolysed at 
different times (non-simultaneously)1. While in other ABC transporters, like ABCC7 (CFTR), 
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hydrolysis of only one ATP molecule is sufficient to drive the transporter back through the 
translocation cycle1. 
Fourth Step: 
The final step of the transport cycle is the release of Pi and ADP, restoring the transporter 
to its basal state. Once the Pi is released the ADP remains bound to the NBDs, however, it 
cannot maintain the stable state of the closed dimer resulting in ADPs release1. Again two 
theories exist of the mechanism behind the release of Pi and ADP, which are based on the 
analysis of the structure of HlyB (via exit channels) and LolD (following electrostatic repulsion 
of the two NBDs)1. The theory of exit channels suggests that these tunnels found in the NBDs 
are hydrophilic and contain a bound ATP molecule, which after hydrolysis is used for the release 
of Pi1. Since there are two NBDs with two ATPs bound to them, there are also two tunnels. One 
tunnel provides continuous passage from one ϒ-phosphate to the surface of the dimer, while the 
other tunnel extending from the ϒ-phosphate of the second ATP is closed by a salt bridge, 
explaining the non simultaneous hydrolysis of the two ATP molecules1. Therefore, it has been 
concluded that one Pi leaves the closed NBD dimer via exit tunnel without any build up of 
electrostatic charge1. The remaining ADP is unable to stabilise the NBD dimer, and the 
dissociation of the NBDs results after which the energy stored in the conformation is released to 
displace the ADP1. The second theory that has been proposed is that the electrostatic repulsion 
between the ADP coordinated by the core sub-domain of one NBD and the Pi coordinated by the 
signature motif of the other NBD destabilises the closed NBD dimer, leading to Pi and ADP 
release1. Once this occurs the transporter is restored to its basal state. 
This four step process of ligand translocation gives us a general idea of how this 
mechanism works. There might have been some minor details that were omitted, but this process 
allows us to have better understanding of function of the ABC transporters. 
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6. Relevance to Drug Resistance: 
For some time now, ABC transporters have been known for their role in the development 
of resistance to therapeutic agents, which is a very common problem in infectious diseases as 
well as in cancer. Cells recognize medication as a toxic compound, and in order to protect the 
organism from the toxic substance they expel it out of the cell which may eventually lead to 
resistance. Patients who are receiving a therapeutic agent may develop resistance to that agent, 
and as a result also may develop resistance to several other therapeutic agents5. The way that 
cells develop this resistance can be acquired in several different ways some of which include: 
decreased uptake, increased detoxification, alteration of target proteins, or increased excretion12. 
Over-expression of the protein results in the increased excretion, which is the key behind drug 
efflux transporter mediated resistance5. Hence, this has been the main concern in humans 
regarding resistance to chemotherapeutic agents5. However, it is also important in eukaryotic as 
well as prokaryotic resistant microorganism5. There are a number of efflux transporters in 
leukemia and in tumour that are responsible for resistance, however, there are only three main 
proteins which are responsible for almost all the resistance occurring in neoplastic cells14, which 
include P-gp, MRP1 and BCRP4. There are five more known ABC transporters which are also 
considered to be responsible for resistance in cancer cells; MRP2, MRP3, MRP4, MRP5 and 
MRP614. In general P-gp and BCRP preferentially extrude large hydrophobic, positively charged 
molecules, while the members of the MRP family can extrude both hydrophobic uncharged 
molecules and water-soluble anionic compounds5. Some of the examples of substrates which are 
transported by these three main transporter proteins are seen in Table 2. 
Table 2: Specific Substrates of P-gp11, MRP11, 15 and BCRP 11, 16 
ABC Transporter  Specific Substrates 
P-gp  Colchicine, etoposide, quinidine, vinblastin, tacrolimus, adriamycin, bilirubin, peptides, lipids, 
steroids,protease inhibitors, xenobiotics, cardiac glycosides, glucocorticoids, non-nucleoside reverse 
transcriptase inhibitors 
MRP 1  Doxorubicin, daunorubicin, vincristine, colchicines, VP-16, etoposide, rhodamine, S-nitrosoglutathione, 
17β-estradiol-17β-D-glucuronide 
BCRP  Anthracycline, topotecan, mitoxantrone, doxorubicin, CPT-11, daunorubicin, rhodamine, prazocin, 
methotrexate, flavopiridol, idarubicinol, epirubicin, topotecan 
20 
 
For a better understanding of the mechanism behind ABC transporters influence in 
resistance, we shall examine the P-gp function in more detail. P-gp is able to cause the highest 
resistance to bulky amphipathic drugs, such as paclitaxel (taxol) and anthracyclines17. The 
hydrophobic parts of these drugs allow their rapid insertion into the membrane17. The 
hydrophilic residues prevent rapid flipping of the drug to the inner leaflet of the membrane, 
slowing down entry into the cell; in fact, for an anthracycline like doxorubicin (Adriamycin) this 
takes about a minute, giving the P-gp pump plenty of time to deal with the influx of 
doxorubicin17. 
Extensive research has been conducted in regards to overcoming resistance and different 
methods have been postulated in which chemotherapy could be improved. One very prominent 
method is the inhibition of efflux transporters which are responsible for the multi drug resistance. 
In order for this method to work, these inhibitors must be highly specific to the efflux 
transporters present in the neoplastic cells. An example of a potent inhibitor of transport function 
is vanadate, which is able to stabilize NBD dimer with one ATP molecule and one ADP 
molecule. This occurs during the third stage of the transport cycle after ATP hydrolysis, once the 
Pi is released and exits the NBD dimer it can be replaced by vanadate causing the transporter to 
be shunted into a stable conformation4, 18. Biochemical evidence suggests that it is an activated 
state with a distinct conformation of the TMDs of P-gp, which remains with a low affinity 
towards vinblastin4,18. Inhibitors such as vanadate have the ability to treat drug resistance in 
cancer, including eukaryotic as well as prokaryotic resistant microorganisms4. 
The investigation of the interactions between drug efflux transporters and their substrates 
or inhibitors is through the development of various in vitro and in vivo experimental models. 
These models can be used for detection of new therapeutic agents that interact with drug efflux 
transporters. Thus specifically identifying the agents to which the neoplastic cells may be 
resistant towards, prior to their development and introduction to the market. Furthermore, they 
can also help to identify the agents which cause inhibition of ABC transporters and can be 
potentially used to enhance drug bioavailability and efficacy.  
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7. In vitro and in vivo models of drug efflux transporters 
 Since the discovery of drug efflux transporters and the role they partake in the 
impairment of efficacy of therapeutic agents, scientists have been searching for a solution to 
resolve this problem. This research has taken us towards the development of numerous in vitro 
and in vivo models of ABC transporters that allow the discovery of interactions between efflux 
transporters and their potential substrates or inhibitors. Different models allow the focus on the 
activity of transporters including the early identification of therapeutic agent, kinetic parameters, 
directionality of transport and tissue specificity of a particular drug efflux transporter19.  
 
7.1 In vitro Models 
 Different types of in vitro methods are used to examine the activity of efflux transporters, 
and the selection of each method depends on the desired output19. In vitro assays might be 
divided into three main categories: accumulation/efflux assays, transport assays and ATPase 
activity assays19. Both parental and transfected cells over-expressing a particular drug efflux 
transporter are employed. 
Initially accumulation and efflux studies will be discussed, which can be done using cell 
suspension, cell monolayer, or membrane vesicles19. In these studies, the translocation of 
selected compound into or out of the cells across the plasmatic membrane is investigated. The 
most common method to trace the localization of tested substrate is by using a probe which is 
typically either fluorescent or radiolabeled. The final location of these probes indicates whether 
the substrate movement across the cell membrane is influenced by the efflux transporter19. 
Accumulation studies examine the movement of the probes into the cells or membrane vesicles 
under controlled experimental conditions, and in the presence or absence of specific inhibitors of 
the drug efflux transporter19. If the tested compound is a substrate of the efflux transporter, the 
addition of the inhibitor will result in an increase of the probe amount in the cells. During efflux 
studies, cells are pre-loaded with the probe of interest and the resulting transport of the probe out 
into the extracellular environment is measured under various conditions known to influence 
transporter activity19,20. One of the main outcomes of these studies is the detection of new 
potential therapeutic agents which inhibit the transporters activity. Hence, the 
accumulation/efflux method can be used in early stages of drug research. Therapeutic agents 
showing initial activity in the first screening assay can then be subjected to further investigation, 
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using additional in vitro or in vivo functional assays to provide more detailed information about 
actual activity of the compounds19.  
Second group of in vitro methods are the transport assays, which has the same function as 
accumulation/efflux assay that is to identify the agent’s specificity to the efflux transporters. This 
is accomplished by using confluent cell monolayer cultured on a permeable membrane support 
matrix19. A variety of cells may be used for this assay, however, they must express the drug 
efflux transporter of interest, and form a functional polarized cell monolayer together with tight 
extracellular junctions19. In order to express the transporter of interest, these cells are transfected 
with a plasmid carrying the coding sequence of a particular efflux transporter. According to its 
type the transporter, they can be localized either on the apical or basolateral side of the cell 
monolayer thus affecting the transport of the substrate in different directions. Successfully 
transfected cells are then used to identify the agents which are specific to the individual 
transporter19. Once the assay is ready, the fluorescent or radiolabeled agent is placed on the cell 
monolayer in three possible ways: on the apical side, on the basolateral side or equal 
concentrations on both the apical and basolateral sides (known as equilibrium transport assay)19. 
In order to determine whether the tested compound is a substrate of the particular efflux 
transporter, the flux of the tested compound across the confluent cell monolayer must be 
measured. In the case of application of substrate on the apical or basolateral side, the activity of 
the transporter can be determined through bidirectional difference in compound permeability 
which can be influenced by inhibitors19. In the equilibrium transport assay, the distribution of the 
agent, up to 48 hours, is followed by expressing the apical to basolateral ratio of the agent 
allowing the activity of the efflux transporter to be obtained19. Transport assays can be used to 
determine the effect of drug efflux transporters on the permeability of the agents, as well as to 
help identify cellular localization of the drug efflux transporters in plasma membrane19,21. 
Finally, the last in vitro methods are ATPase assays. As it can be seen from its name it 
incorporates the ATPase activity of the transporters, monitoring the hydrolysis of ATP. Since all 
ABC transporters require ATP to move their substrates across the cell membrane, hydrolysis will 
indicate which substrate is specific to the selected drug efflux transporter19,22. Components 
required for this ATPase assay are: cell membrane preparation enriched with the transport 
protein of interest, ATP, analytical method for the detection of inorganic phosphates generated 
from ATP hydrolysis, and a mechanism discriminating between general ATPase activity and 
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ATPase activity related to the transport of interest19. The ATPase activity of the specific 
transporter in question is distinguished from other ATPase activity through the inclusion of 
various inhibitors such as ouabain or azide which inhibit Ca-ATPase, Na/K-ATPase and 
mitochondrial ATPase respectively19. The ATPase assay is also used to identify substrates 
specificity of the transporters, as well as to identify the inhibitors. ATPase assays have been used 
most extensively in examining P-gp drug efflux transporter19. ATPase assays can also be used to 
examine the changes in basal ATPase activity to quantitatively determine potential differences in 
the affinity of compounds for drug efflux transporters19,23. 
 
7.2 In vivo Models 
 In vivo models examine the activity of drug efflux transporters slightly different then in 
vitro models. In vitro models are used to determine interaction between transporters and their 
substrates as opposed to in vivo models, which examine the influence of the transporter on 
absorption, distribution and elimination of the therapeutic agents in the organism19. Transgenic 
and mutant animals are the most common in vivo models used19. 
 Transgenic models are genetically modified animals where the transporter of interest can 
be either deleted or overexpressed19. The way these transporters are deleted or expressed is done 
through a process called gene knockout or homologous recombination19. In this process, the 
targeting vector carrying the DNA sequences which are homologous to the genes of interest are 
introduced into an embryonic stem cell19. The insertion of the sequence into the stem cell causes 
the target gene to be inactive producing desired embryonic stem cells that express this inactive 
gene. Once it is identified, it is injected into the blastocysts and is implanted into the foster 
mothers19.  The offspring are examined for the disrupted alleles and inbred to produce a stable 
line of animals which are homozygous for the deleted gene19. The usual selected animal is 
mice19.  P-gp and MRP-1 have been the two most widely used efflux transporters employed in 
the transgenic models. When examining P-gp a slight difference in the human and mice genome 
needs to be acknowledged, as mice have two genes encoding the P-gp mdr1a and mdr1b, while 
humans have only one gene (MDR1) encoding this transporter19. Hence, in order to examine P-
gp function in drug pharmacokinetics and efficacy, one or both of these genes need to be 
knocked out19. This has led to a number of studies for a better understanding of P-gp function, 
such as its role in maintaining the integrity of the blood brain barrier, but most importantly its 
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understanding in disposition and elimination of different substrates19. The significance of these 
studies is the substrate, which may be identified using in vitro efflux transporters models and on 
the other hand may not be identified as a substrate in more complex animal models such as the 
transgenic model. Hence, allowing the transgenic model to confirm whether the transporter 
actually affects the substrate kinetics in live animals19. 
 The second in vivo model on the other hands is composed of two mutant animals, which 
are not genetically modified, but are rather naturally mutated to lack the transporter proteins that 
are responsible for resistance. The first mutant model is a sub-population of the CF-1 mouse that 
exhibits a genetic defect, resulting in the absence of P-gp expression19. This genetic defect occurs 
in mdr1a gene where an insertion of DNA occurs at exon 23, resulting in aberrant splicing of the 
mRNA and the loss of exon 23 during RNA processing19. The sub-family has been bred to 
produce off-springs that display this phenotype for further evaluation of P-gp function in 
pharmacokinetics, disposition and toxicity19. The second mutant model is known as TR(-) rat, 
which lacks the gene for mrp219. It is described as autosomal recessive conjugated 
hyperbilirubinemia, which displays impaired biliary excretion of conjugated bilirubin due to the 
naturally occurring deficiency in mrp2 gene19. This mutant model has been primarily used as an 
animal model for Dubin-Johnson syndrome, since the phenotype of the TR(-) mutants is similar 
to the Dubin-Johnson syndrome in humans19. Additionally, it is used to study the absorption, 
distribution, metabolism and excretion of substrates, and elimination of their metabolites19. For 
example, the biliary elimination of acetaminophen glucuronide, where more than a 300-fold 
decreased in biliary excretion of acetaminophen glucuronide is observed in TR(-) rats compared 
to wild type controls19. Further research has also resulted in observing lower biliary excretion of 
both parent molecules and metabolite of in anticancer agents19. Both of these models are 
important in the study of efflux transporter protein activity in a living organism, giving us further 
clues as to how to treat different diseases as well as overcome transporter mediated multidrug 
resistance.  
Since the mice genes vary from the humans genes, there are different considerations we 
need to for take when concluding the results derived from these animal studies. As explained 
before, the P-gp of the mice has two genes the mdr1a and mdr1b which induce drug resistance, 
thus silencing only one of these two genes might not be sufficient in fully suppressing the P-gp 
expression19. Certain organs of the mice might express one of the two genes or both, therefore 
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depending on the organ that is being studied they can still remain functional despite the removal 
of one of the genes19. Additionally, due to organism natural ability to compensate for certain 
defects such as in the case of a missing gene, the organism has the ability to overcome this by 
expressing other genes related to the missing one, such is the case for P-gp mdr1b gene19. When 
the mdr1a gene is genetically removed, there is an up-regulation of the mdr1b gene in the kidney 
and liver19. However, if the mdr1b gene is genetically removed there is no up-regulation of the 
mdr1a gene19. This removal of the genes can lead to undesirable outcomes such as altered 
pharmacokinetics, lack of viability or system toxicity, since it affects other organs than just the 
one of interest19. Hence, it would be ideal to develop a model which would knockout the genes 
of interest but also selective to the specific organs19. When comparing the human MDR1 
(responsible for human P-gp) to mdr1a and mdr1b (mice P-gp) expressing cells, they 
demonstrate species dependent substrate specificity of P-gp19. Although majority of compounds 
which are indentified as P-gp substrates in the mutant CF-1 model and the transgenic mdr1a 
over-expressing model are also likely to be substrates for human P-gp, there is a great potential 
for either under- or over-estimation of drug susceptibility to P-gp in humans19. Here, the 
combination of in vitro and in vivo models is developed to overcome this problem19. The human 
in vitro assays are used to form and compare the results to those observed in the mice in vivo 
models to identify differences in P-gp substrate specificity of the two species19.  
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8. Aim of Study: 
 The goal of this study was to prepare a universal plasmid (pZSV5 or pLNCXV5), which 
contains a short sequence of V5 tag. The V5 epitope tag is derived from a small epitope (Pk) 
present on the P and V proteins of the paramyxovirus of simian virus 5 (SV5). The V5 tag is 
usually used with all 14 amino acids (GKPIPNPLLGLDST), although it has also been used with 
a shorter 9 amino acid sequence (IPNPLLGLD). The V5 tag functions as a universal marker of 
protein expression, which could be detected by immunoanalytical methods (e.g. Western blot 
analysis). The newly prepared pZSV5 or pLNCXV5 plasmid enables the cloning of coding 
sequences of selected drug efflux transporters enabling the localization of V5 tag on their C-end. 
The final construct carrying the coding sequence of the desired efflux transporter can be then 
used for production of stable transfected cell lines which will serve as an in vitro model for 
investigation of drug efflux transporters. 
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9. Materials and Methods  
 
9.1.1 Materials 
 
All restriction enzymes were commercial obtained from New England Biolabs (Ipswich, 
Massachusetts, USA). The DNA markers used for gel electrophoresis were obtained from 
Fermentas (St. Leon-Rot, Germany). pZeoSV2(-) plasmid was purchased from Invitrogen Life 
Technologies (Carlsbad, California, USA). pLNCX2 retroviral plasmid was purchased from 
Clontech (Mountain View, California, USA). All oligonucleotides used for V5 tag were 
produced at Generi Biotech (Hradec Kralove, Czech Republic). RecoChip used for isolation of 
DNA from agarose gel after gel electrophoresis was obtained from Takara (Madison, Wisconsin, 
USA). 
 
9.1.2 Equipment  
 
For cell culture Binder Incubator was used (Vienna, Austria). Incubator with mixing 
capability of 220 rpm was from New Brunswick Scientific (Edison, New Jersey, USA). For 
sample centrifugation, different centrifuges were used: Sigma Laboratory Centrifuge 4K15C 
(Osterode am Harz, Germany), Eppendorf minispin centrifuge (Horsholm, Denmark) and Scan 
Speed 1730R centrifuge (Narellan, Australia). For brief mixing bio vortex from Biosan (Warren, 
Illinois, USA) was employed. Gel electrophoresis was performed using Hoefer HESS Mini 
Horizontal Submaine Unit and Bio-Rad power pack (Hercules, California, USA). Visualization 
and analysis of the gel was accomplished in G-box from Syngene (Cambridge, Great Britain) 
using the Gene Snap software. Concentration of DNA was measured using Spectrophotometer 
Nanodrop ND-1000 (Wilmington, North Carolina, USA). Transformation and isolation of E.coli 
was carried out in Biohazard box Aura 2000 BS (Pavia, Italy). Samples were heated in Omni 
Gene Heater (Kent City, Michigan, USA). For pipetting automatic pipettes from Eppendorf 
(Horsholm, Denmark) were used. 
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9.2 Cloning of pZSV5 and pLNCXV5 plasmids 
 
9.2.1 Cloning Scheme of pZSV5 
 The pZSV5 plasmid is a modified commercial pZeoSV2(-) plasmid obtained from 
Invitrogen Life Technologies (Figure 5). 
 
 
Figure 5: pZeoSV2(-) plasmid map. This figure was obtained from Invitrogen life technologies 
lab manual24 
 
pZeoSV2(-) is a 3.45 kb vector which contains antibiotic (zeocin) resistance gene, 
allowing selection in both prokaryotes and eukaryotes24. This vector contains multiple cloning 
site, which enables the insertion of desired DNA sequences of interest (in our case the ABC 
transporter as well as the V5 tag). The expression of cloned DNA in mammalian cells is driven 
by potent eukaryotic PSV40 promoter. 
At first the artificial sequence of the V5 tag has been designed so that it codes for the 14 
amino acids (GKPIPNPLLGLDSTGTHHHHHH) of the natural V5 tag, six amino acids of 6-His 
tag (6xHis) separated from V5 tag by glycine (G) and threonine (T), and TGA stop codon at the 
end (Figure 6). 
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Figure 6: Amino acid and nucleotide sequences of the V5 tag 
 
 To enable cloning of the V5 tag DNA into the pZeoSV2(-) cohesive ends enabling the 
insertion of the sequence into XhoI and NotI restriction sites have been added to 5’- and 3’-end 
of the artificial sequence, respectively. Cohesive ends have been designed so that the restriction 
sites were annihilated after successful ligation. Furthermore, recognition sites for SpeI, XbaI, 
NotI and EcoRI were included into the sequence to allow for cloning of coding sequences of 
desired efflux transporters in frame with artificial V5 tag located on their C-end (table 3 lists 
different restriction endonucleases used for cloning of different transporters into pZeoSV2-). The 
resulting length of the V5 tag is 96 bp (Figure 7). For detailed scheme of the cloning procedure 
refer to Figure 8. 
 
 
Table 3: List of restriction endonucleases with their recognition sites  
 
  
XhoI C|TCGAG 
GAGCT|C 
SpeI A|CTAGT 
TGATC|A 
NotI GC|GGCCGC 
CGCCGG|CG 
XbaI T|CTAGA 
AGATC|T 
EcoRI G|AATTC 
CTTAA|G 
 
 
 
 
 
 
 
TCGACTAGTTCTAGAGCGGCCGCGGCAAGCCCATCCCCAACCCCCTGCTGGGCCTGGACAGCACCGGTACCCATCATCACCATCACCATTGAATTC 
     GATCAAGATCTCGCCGGCGCCGTTCGGGTAGGGGTTGGGGGACGACCCGGACCTGTCGTGGCCATGGGTAGTAGTGGTAGTGGTAACTTAAGCCGG 
 
Figure 7: Double Stranded Sequence of V5 tag 
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Map of pZeoSV2(-) plasmid                                                Map of plasmid + V5tag  
                                         
                                                                                                                
                  Map of plasmid + BCRP + V5 tag 
Figure 8: Cloning scheme of BCRP into pZSV5. 
To clone the DNA of interest (V5 tag and ABC transporter) into pZeoSV2(-), the plasmid is first 
digested either by XhoI or NotI restriction endonucleases. The sequence of V5 tag is inserted via 
ligation with the linearized plasmid, forming the new pZSV5 plasmid. This plasmid can be 
further digested using SpeI/XbaI and NotI restriction endonucleases, to enable the insertion of the 
cDNA of selected efflux transporter in frame with the V5 tag sequence, so that the resulting 
protein is produced with the V5 tag on its C-end. In our case the selected transporter was BCRP.  
 
9.2.2 Cloning Scheme of pLCXV5 
pLNCX2 is a retroviral plasmid which was also used to ligate with the V5 tag, as an 
alternative to the pZeoSV2(-) plasmid.  pLNCX2 is a ~ 6.1 kb retroviral vector which contains 
antibiotic (neomycin) resistance gene, allowing selection in eukaryotes25. This vector contains 
multiple cloning site, which enable insertion of desired DNA sequences of interest (in our case 
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the ABC transporter as well as the V5 tag), seen in figure 9. The expression of the desired cDNA 
is eukaryotic cells is driven by potent PCMV IE promoter. 
 
 
Figure 9: pLNCX2 plasmid map25. This figure was obtained from Clontech lab manual 
 
The V5 tag DNA used to clone into pLNCX2 retroviral plasmid was the same one used to 
clone into pZeoSV2(-) plasmid (figure 5). In order to clone the V5 tag DNA into the pLNCX2 
retroviral plasmid restriction endonucleases XhoI and NotI were used to digest and linearize the 
plasmid. Restriction endonucleases s SpeI/XbaI and NotI can further be used to clone the coding 
sequence of desired efflux transporter into the pLNCXV5 plasmid so that the resulting proteins 
are produced with the artificial V5 tag located on their C-end (table 4 lists different restriction 
endonucleases s used for cloning of different transporters into pLNCX2). For detailed scheme of 
the cloning procedure refer to Figure 10. 
 
Table 4: List of restriction endonucleases with their recognition sites 
 
XhoI C|TCGAG 
GAGCT|C 
SpeI A|CTAGT 
TGATC|A 
NotI GC|GGCCGC 
CGCCGG|CG 
XbaI T|CTAGA 
AGATC|T 
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 Map of pLNCX2 plasmid     Map of plasmid + V5 tag 
 
                   
 
    
 
                Map of plasmid + BCRP + V5 tag 
Figure 10: Cloning scheme of BCRP into pLNCX2 
To clone the DNA of interest (V5 tag and ABC transporter) into pLNCX2, the plasmid was first 
digested using XhoI and NotI restriction endonucleases. The sequence of V5 tag was inserted via 
ligation with the linearized plasmid, forming the new pLNCXV5 plasmid. This plasmid was 
further digested using XbaI and NotI restriction endonucleases, to enable the insertion of the 
cDNA of selected efflux transporter in frame with the V5 tag sequence. In our case the selected 
transporter was BCRP. Thus, the final plasmid enables the expression of BCRP transporter with 
V5 tag sequence at its C-end.  
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9.2.3 Preparation of V5 tag 
The artificial double stranded DNA sequence of the V5 tag has been assembled either 
from hybridization and subsequent ligation of four short sequences of oligonucleotides (V5N1, 
V5N1r, V5N2 and V5N2r, refer to Figure 11) or from simple hybridization of two 
oligonucleotides (V5_F and V5_R, refer to Figure 12).  
 
V5N1: TCGACTAGTTCTAGAGCGGCCGCGGCAAGCCCATCCCCAACC 
V5N1r: GTCCAGGCCCAGCAGGGGGTTGGGGATGGGCTTGCCGCGGCCGCTCTAGAACTAG 
V5N2: CCCTGCTGGGCCTGGACAGCACCGGTACCCATCATCACCATCACCATTGAATTC 
V5N2r: GGCCGAATTCAATGGTGATGGTGATGATGGGTACCGGTGCT 
Figure 11: Short V5 tag oligonucleotide sequences 
 
V5_F: TCGACTAGTTCTAGAGCGGCCGCGGCAAGCCCATCCCCAACCCCCTGCTGGGCCTGGACAGCACCGGTACCCATCATC 
V5_R: GGCCGAATTCAATGGTGATGGTGATGATGGGTACCGGTGCTGTCCAGGCCCAGCAGGGGGTTGGGGATGGGCTTGCCG 
Figure 12: Long V5 tag oligonucleotide sequences 
 
Different temperature and concentration profiles have been used to optimize the 
hybridization of oligonucleotides. The first temperature profile involved incubating Mixtures A 
(V5N1+V5N1r) and B (V5N2+V5N2r) at 80°C for 2 minutes. The second temperature profile 
was completed in such a way that Mixtures A (V5N1+V5N1r) and B (V5N2+V5N2r) were 
heated for 3 minutes at 90°C, followed by a 10 minutes long decrease in temperature to 70°C, 
then heated for 3 minutes at 70°C, followed by slow 10 minute temperature decrease to 37°C and 
finally were heated for 3 minutes at 37°C. The third optimization profile involved incubating 
mixtures of two different concentrations; Mixture 1A (V5N1+V5N1r) and 1B (V5N2+V5N2r) 
were diluted ten times while the second Mixture 2A (V5N1+V5N1r) and 2B (V5N2+V5N2r) 
were mixed using the original stock concentration.  Mixtures 1A, 1B, 2A and 2B were incubated 
at 95°C for 3 minutes and further incubated at room temperature over night. During this process 
denaturation and hybridization of complementary sequences of oligonucleotides occurred.  
For hybridization of cohesive ends of hybridized oligonucleotides the A and B mixtures 
were mixed together and heated for 5 minutes at either 40°C or 95°C, then allowed to cool at 
room temperature for 20 to 60 minutes, respectively.  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To hybridize the oligonucleotides V5_F and V5_R two starting concentrations were 
tested: 10-times diluted mixture 3 (V5_F+V5_R) and undiluted mixture 4 (V5_F+ V5_R). Both 
samples were incubated at 95°C for 3 minutes, and then allowed to cool at room temperature 
over night. 
 To complete the assembly of the V5 tag DNA from the oligonucleotides (V5N1, V5N1r, 
V5N2 and V5N2r) the final step of the process was ligation. Once the hybridization of cohesive 
ends was complete T4 DNA Ligase and T4 DNA Ligase buffer were added to the mixture, and 
incubated at room temperature for 20 to 60 minutes. In this final step ligation of the DNA 
fragments occurs, producing the desired artificial V5 tag DNA. 
In order to determine whether the V5 tag DNA was successfully created and to isolate the 
sequence, gel electrophoresis method was employed. The V5 tag DNA was separated on agarose 
gel (2.0% or 2.5%). The gel used was submerged in 1xTris-borate (1xTBE) buffer and the DNA 
fragment mixed with sample buffer was placed into selected well of the gel. DNA ladder was 
used to estimate the molecular weight of the fragment. Once the separation was complete it was 
viewed under a fluorescent lamp and visualized using ethidium bromide present in the gel. Upon 
successful identification of the V5 tag DNA, which is approximately 100 bp long, it was isolated 
using the RecoChip membrane. The membrane was placed into the gel in front of the desired 
band, then the electricity was turned on allowing the molecule to attach to it. The chip was later 
placed in a centrifuge and all of the bound plasmid or DNA on the chip was spun down, thus 
isolating the V5 tag. 
  
9.2.4 Cloning of V5 tag into pZeoSV2(-) 
Once the V5 tag was prepared and isolated it was further cloned into the pZeoSV2(-). 
The plasmid was first digested by previously mentioned restriction endonucleases s XhoI and 
NotI. Upon completion of digestion of the plasmid, the plasmid was separated on 0.7% agarose 
gel using gel electrophoresis method. Once successfully identifying the linearized plasmid, it was 
isolated using the RecoChip membrane (refer to the previous paragraph in section 8.2.3, on 
isolation of DNA from the agar gel). 
The next step was the ligation of the isolated linearized plasmid with the V5 tag. During 
optimization different ratios of plasmid and insert have been tested, these include 1:2, 1:3, 1:5, 
1:6, 1:9, 1:10 and 1:20. In ligation reaction the T4 DNA Ligase (along with T4 DNA Ligase 
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buffer) was used to clone V5 tag into the linearized plasmid, through the formation of 
phosphodiester bonds between the 3’ hydroxyl end and a 5’ hydroxyl end of DNA strands. Once 
the linearized plasmid and the V5 tag DNA optimization ratios have been chosen, they were 
mixed and heated at 55°C for 2 minutes and rapidly cooled on ice. After which T4 DNA Ligase 
(along with T4 DNA Ligase buffer) was added to the mixture and incubated at room temperature 
for 20 minutes to complete the ligation of the plasmid and V5 tag. 
The ligation mixture was then transformed into Escherichia coli (E.coli) competent cells 
(strain dh5α) using the heat-shock method. First E. coli cells were mixed together with the 
ligation mixture, incubated on ice for 30 min and then heat shocked (42°C for 90 seconds). The 
heat shock forms pores in the cell membrane of the bacteria enabling the plasmid enter the cell. 1 
mL of SOC (Super Optimal broth with Catabolite repression) medium was added to this mixture 
and incubated for an hour at 37°C/220 rpm. Once the transformation was complete the 
suspension was placed on the agar dish containing zeocin thus allowing only the transformed 
cells to grow. The dish was incubated at 37°C overnight. The next day most developed colonies 
were selected, re-picked onto a new zeocin agar dish and cultivated in the incubator at 37°C 
overnight. Simultaneously the cells were placed into the test tube with preheated zeocin LB 
(Lysogeny Broth) medium and allowed to grow at 37°C/220 rpm overnight. These colonies of 
bacteria multiply in the medium and with their multiplication also increased the concentration of 
the plasmid. The next day the bacterial cells were spun down and the pellet was used to harvest 
this highly copied DNA plasmid using the Plasmid DNA Purification kit obtained from 
Macherey-Nagel (Duren, Germany). 
Once the purified plasmid was isolated from the bacteria the insertion of the V5 tag was 
verified by restriction analysis using either BsaWI or combination of AgeI and BpmI restriction 
endonucleases. Length of resulting fragments was visualized on the 0.7% agarose gel indicating 
whether the cloning was successful (the two different restriction analysis with resulting fragment 
lengths are seen in table 5).  
 
Table 5: Restriction endonucleases used to digest pZSV5 and resulting fragment lengths  
 
Restriction endonucleases  Resulting fragment length 
AgeI + BpmI 1178, 2426 
BsaWI 147, 1511, 1856 
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9.2.5 Cloning of V5 tag into pLNCX2 
The V5 tag DNA used to clone into pLNCX2 retroviral plasmid was the same one used to 
clone into pZeoSV2(-) plasmid. The plasmid was first digested using restriction endonucleases 
XhoI and NotI, after which the plasmid was separated on the 0.7% agarose gel using the gel 
electrophoresis method. Upon successful identification of the linearized plasmid, it was isolated 
using the RecoChip membrane (refer to section 8.2.3, on isolation of DNA from the agar gel 
using RecoChip membrane). 
The next step was the ligation of the linearized plasmid with the V5 tag. The optimization 
ratio of linearized plasmid and the insert which was tested was 1:3. To the ligation mixture the 
T4 DNA Ligase (along with T4 DNA Ligase buffer) was added to clone V5 tag into the 
linearized plasmid. The whole process was carried out by mixing the linearized plasmid and the 
V5 tag DNA together and heating the mixture at 55°C for 2 minutes then rapidly cooling the 
mixture on ice. The next step was the addition of T4 DNA Ligase (along with T4 DNA Ligase 
buffer) which was incubated at room temperature for 20 minutes to complete the ligation of the 
plasmid and V5 tag. 
The ligation mixture was then transformed into E. coli competent (strain dh5α) cells 
using the heat-shock method (refer to method 8.2.4). Once the transformation was complete the 
suspension was placed on the agar dish containing neomycin thus allowing only the successfully 
transformed cells to grow. The dish was incubated at 37°C overnight. The next day most 
developed colonies were selected, re-picked onto a new neomycin agar dish and cultivated in the 
incubator at 37°C overnight. Simultaneously the cells were placed into the test tube with 
preheated neomycin LB medium containing neomycin and allowed to grow at 37°C/220 rpm 
overnight. The next day bacterial cells were spun down and the pellets were used to harvest the 
highly copied DNA plasmid using the Plasmid DNA Purification kit obtained from Macherey-
Nagel (Duren, Germany). 
Once the purified plasmid was isolated from the bacteria the insertion of the V5 tag was 
verified by restriction analysis using either EcoRI or SpeI restriction endonucleases. Length of 
resulting fragments was visualized on the 0.7% agarose gel indicating whether the cloning was 
successful (two different restriction analysis with resulting fragment lengths are seen in table 6). 
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Table 6: Restriction endonucleases used to digest pLNCXV5 and resulting fragment lengths  
 
Restriction endonucleases  Resulting fragment length 
EcoRI  1551, 1613, 3038 
SpeI  2208, 3994 
 
 
9.2.6 Amplification of BCRP cDNA 
To amplify the cDNA of BCRP transporter using PCR one forward (hABCG2 v5f) and 
two different reverse primers were employed (hABCG2 v5r or hABCG2 v5r 2) (Figure 13). 
 
Figure 13: Forward and Reverse primer sequences 
 
 The use of hABCG2 v5r reverse primer lead to amplification of the whole BCRP 
sequence, unlike the employment of hABCG2 v5r 2 produced BCRP sequence which is of 24 
nucleotides shorter. Phusion polymerase (Finnzymes, Thermo Fisher Scientific, Vantaa, Finland) 
was employed for cDNA amplification in iQ Thermal Cycler (Bio-Rad, Hercules, California, 
USA) under the following conditions: 1 mM MgCl2, 0.2 mM dNTP, 0.01 U/µL polymerase and 
0.3 µM of each primer. To optimize the annealing step of the reaction temperature gradient was 
applied (50°-60°C). The resulting profile was as follows: 98°C for 30 seconds, 50 to 62 repeats 
of cycle consisting of 98°C for 7 seconds, 50°-62°C for 15 seconds and 72°C for 60 seconds. 
Resulting PCR products were separated on 0.7 % agarose gel and visualized under UV 
light. The best amplified sample was selected and isolated from the gel using RecoChip 
membranes and prepared for cloning into either the pZSV5 or pLNCXV5 plasmids.  
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10. Results: 
 
10.1.1 Preparation of V5 tag employing four oligonucleotides 
 
The first part of the experiment involved preparing the V5 tag sequence using 
hybridization and further ligation of short sequences of oligonucleotides (V5N1, V5N1r, V5N2 
and V5N2r). To get the desired sequence, different temperature profiles of hybridization were 
used. The first profile tested was: mixtures A (V5N1+V5N1r) and B (V5N2+V5N2r) were 
incubated at 80°C for 2 minutes. The reaction mixture was loaded on 2.5 % agarose gel and 
resulting V5 tag was visualised using gel electrophoresis method under UV light. As it can be 
seen from the photo of the gel (Figure 14) no clear band of the V5 tag was observed. Moreover, 
lots of impurities forming a smear can be seen on the gel. This indicated that the hybridization 
and ligation of oligonucleotides did not occur completely and that the temperature profile used 
did not lead to proper formation of V5 tag. 
 
 
Figure 14: Photo of gel electrophoresis of V5 tag hybridization using the following temperature 
profile; mixtures A (V5N1+V5N1r) and B (V5N2+V5N2r) were incubated at 80°C for 2 minutes 
 
Another tested temperature profile of hybridization was: mixtures A (V5N1+V5N1r) and 
B (V5N2+V5N2r) which were heated for 3 minutes at 90°C, followed by a 10 minutes decrease 
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in temperature to 70°C, then heated for 3 minutes at 70°C, followed by slow 10 minute 
temperature decrease to 37°C and finally were heated for 3 minutes at 37°C. When the reaction 
mixture was separated and visualized using gel electrophoresis method a clear band of molecular 
length around 100 bp was observed (refer to figure 15). This band corresponded with the 
expected position of the 96 bp long V5 tag, suggesting that the selected conditions of 
hybridization lead to proper assembly of oligonucleotides. The band was isolated from the gel 
via RecoChip membrane and used further in the cloning process.   
 
Figure 15: Photo of gel electrophoresis of V5 tag hybridization using the following temperature 
profile; mixtures A (V5N1+V5N1r) and B (V5N2+V5N2r) were heated for 3 minutes at 90°C, 
followed by a 10 minutes long decrease in temperature to 70°C, then heated for 3 minutes at 
70°C, followed by slow 10 minute temperature decrease to 37°C and finally were heated for 3 
minutes at 37°C. 
 
In the third optimization process two different starting concentrations of oligonucleotides 
were tested, 100 µM and 10 µM. The temperature profile of hybridization was: mixture 1A 
(V5N1+V5N1r) and 1B (V5N2+V5N2r) were diluted ten times (100 µM) while the second 
mixture 2A (V5N1+V5N1r) and 2B (V5N2+V5N2r) were mixed using the original stock 
concentration (10 µM).  Mixtures 1A, 1B, 2A and 2B were incubated at 95°C for 3 minutes and 
further incubated at room temperature over night. The resulting V5 tag was separated and 
visualised using gel electrophoresis method (Figure 16). In case of low starting oligonucleotides 
concentration no clear band corresponding with the expected V5 tag sequence was noted (Figure 
16, lane 1A+1B). These results suggest that the concentration of oligonucleotides was not 
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sufficient to create the desired V5 tag. On the other hand, utilization of undiluted 
oligonucleotides resulted into a thick smeary band on the gel indication that the reaction mixture 
was overloaded (Figure 16, 2A+2B). 
 
 
Figure 16: Photo of gel electrophoresis of V5 tag hybridization using the following temperature 
profiles: the  mixture 1A (V5N1+V5N1r) and 1B (V5N2+V5N2r) were diluted ten times 
(1A+1B in the figure), while the second mixture 2A (V5N1+V5N1r) and 2B (V5N2+V5N2r) 
were mixed using the original stock concentration (2A+2B in the figure).  Mixtures 1A, 1B, 2A 
and 2B were incubated at 95°C for 3 minutes and further incubated at room temperature over 
night 
 
 
10.1.2 Preparation of V5 tag employing two oligonucleotides 
 
Another approach of V5 tag assembly involved hybridizing two oligonucleotide 
sequences (V5_F and V5_R). The hybridization was tested using two different concentrations 
100 µM and 10 µM, which occurred under following temperature profile: 10 times (100 µM) 
diluted mixture 3 (V5_F+V5_R) and undiluted (10 µM) mixture 4 (V5_F+ V5_R). Both samples 
were incubated at 95°C for 3 minutes, and then allowed to cool at room temperature over night. 
After the hybridization process was complete, resulting V5 tags was separated and visualised 
using gel electrophoresis method (refer to figure 17). Lane 3 in figure 17 demonstrates that low 
starting oligonucleotides concentrations did not produce the desired sequence of V5 tag. On the 
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contrary, when the oligonucleotides were mixed undiluted a clear band of an approximate length 
of 100 bp corresponding with V5 tag was observed (Figure 17, lane 4). As a result this band was 
isolated using the RecoChip membrane and used further in the experiment. 
 
 
Figure 17: Photo of gel electrophoresis of V5 tag hybridization was tested using: 10-times (100 
µM) diluted mixture 3 (V5_F+V5_R) in lane 3 and undiluted (10 µM) mixture 4 (V5_F+ V5_R) 
in lane 4. Both samples were incubated at 95°C for 3 minutes, and then allowed to cool at room 
temperature over night. 
 
10.2 Cloning of V5 tag into pZeoSV2(-) 
 
To prepare pZeoSV2(-) plasmid for cloning of the V5 tag into the plasmid, it was first 
digested using the restriction endonucleases which were XhoI and NotI. The whole reaction 
mixture was then loaded on the 0.7% agarose gel and visualized using the gel electrophoresis 
method. The length of 3500 bp was clearly identified when compared to the 1kb DNA ladder. 
The linearized plasmid was isolated using the RecoChip membrane, and further used in the 
experiment (refer to Figure 18). 
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Figure 18: Digestion of pZoeSV2(-) using XhoI and NotI restriction endonucleases. Band of the 
molecular length of 3500 bp was identified as the linearized pZeoSV2(-) plasmid. 
 
 
 For cloning of the V5 tag into the pZeoSV2(-) different optimization ratios of the 
linearized plasmid and insert were tested. The ratios of plasmid to insert which were tested are: 
1:2, 1:3, 1:5, 1:6, 1:9, 1:10 and 1:20. The different ratios of linearized plasmid and V5 tag DNA 
were mixed and heated at 55°C for 2 minutes, and rapidly cooled on ice. After which they were 
ligated using T4 DNA Ligase (along with T4 DNA Ligase buffer) by incubating them at room 
temperature for 20 minutes. The ligated mixture was transformed into E.coli and allowed to grow 
on an agar dish containing zeocin thus allowing only the successfully transformed cells to grow. 
Four of the most developed colonies were selected from each ratio, with ratio 1:3 having the 
most developed colonies and also containing approximately 100 fully grown colonies on the 
plate to choose from. The colonies were further grown and the plasmids isolated (refer to method 
8.2.4). The isolated plasmids were digested using AgeI and BpmI restriction endonucleases do 
determine if the V5 tag was ligated with pZeoSV2(-). The reaction mixture was loaded on 0.7 % 
agarose gel and the resulting plasmids were visualized, as seen in figures 19, 20 and 21. If the 
ligation of V5 tag with the plasmid was successful two clear bands should be observed at 1178 
and 2426 bp on the agarose gel. All three figures give the same negative result, since all the 
ratios after visualization produced three bands which were all identical to the negative plasmid 
indicating that the ligation between pZeoSV2(-) plasmid and the V5 tag did not occur. 
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Figure 19: Restriction analysis of pZSV5. As a negative control original pZeoSV2(-) was used. 
Lanes 1-4: ratio1:3; lanes 5-8:  ratio 1:5; and lanes 9-12: ratio 1:10 
 
 
Figure 20: Restriction analysis of pZSV5. As a negative control original pZeoSV2(-) was used. 
Lanes 1-4: ratio1:5; lanes 5-8:  ratio 1:10; and lanes 9-12: ratio 1:20 
 
 
Figure 21: Restriction analysis of pZSV5. As a negative control original pZeoSV2(-) was used. 
Lanes 1-4: ratio1:2; lanes 5-8:  ratio 1:6; and lanes 9-12: ratio 1:9 
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10.3 Cloning of V5 tag into pLNCX2 
To prepare pLNCX2 plasmid for cloning of the V5 tag into the plasmid, it was first 
digested using the restriction endonucleases XhoI and NotI. The whole reaction mixture was 
further loaded on the 0.7% agarose gel and visualized using the gel electrophoresis method. The 
band length of 6100 bp was clearly identified when compared to the 1kb DNA ladder. The 
linearized plasmid was isolated using the RecoChip membrane, and further used in the 
experiment (refer to figure 22). 
 
 
Figure 22: Digestion of pLNCX2 using XhoI and NotI restriction endonucleases. Band of the 
molecular length of 6100 bp was identified as the linearized pLNCX2 plasmid. 
 
 For cloning of the V5 tag into pLNCX2 plasmid the ration of the plasmid and insert used 
was 1:3. The reaction mixture was transformed into E.coli and allowed to grow on an agar dish 
containing neomycin thus allowing only the successfully transformed cells to grow. Ten of the 
most developed colonies were selected. The colonies were further grown and the plasmids 
isolated (refer to method 8.2.4). To verify that the cloning was correct the isolated pLNCXV5 
plasmids were digested using SpeI or EcoRI restriction endonucleases.  
When EcoRI was used nonspecific results were obtained (Figure 23). In most of the 
samples only two bands of approximately 1500 bp and 3000bp instead of three (1551 bp, 1613 
bp, 3038 bp) were clearly visible under the UV light. On the contrary, the employment of SpeI 
restriction endonucleases revealed positive results in sample No. 1, 2, 3, 5, 6, 8, 9 and 10 (refer 
to Figure 24). The two bands observed at their specific lengths of 2200 bp and 4000 bp indicate 
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that in these samples the insertion of the V5 tag into pLNCX2 did occur. The most promising 
samples included 3, 6 and 8, were further isolated using the RecoChip membrane. 
 
 
Figure 23: Restriction analysis of pLNCXV5 using EcoRI restriction endonucleases  
 
 
Figure 24: Restriction analysis of pLNCXV5 using SpeI restriction endonucleases. Bands of 
molecular length of 2200bp and 4000 bp were identified at their specific lengths indicating that 
the pLNCX2 plasmid was cloned with the V5 tag.  
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10.4 Amplification of BCRP cDNA 
 The BCRP cDNA insert was amplified from human liver cells using PCR method. Two 
different reverse primers were used leading to amplification of either the whole sequence of 
BCRP or coding sequence which was of 24 nucleotides shorter. However, no difference in 
amplification efficiency was observed between these two reverse primers. For annealing four 
different temperatures were analysed: 50°C, 53.4°C, 58.9°C and 62°C. All bands of the 
amplified BCRP cDNA when viewed on the 0.7% agarose gel resulted in specific lengths of 
approximately 2000 bp (Figure 25). Indicating that the BCRP cDNA was amplified correctly and 
that the best annealing temperature occurred at 62°C. The full sequence of BCRP cDNA at 62°C 
was isolated from the gel using the RecoChip membrane and prepared to be used further in the 
experiment. 
 
 
Figure 25: Photo of gel electrophoresis of amplification of BCRP cDNA using four different 
annealing temperatures, which were: 50°C, 53.4°C, 58.9°C and 62°C. CDS3 in this figure 
indicates that four samples of amplified BCRP were created using hABCG2 v5r reverse primer 
at temperatures specified previously, and lead to amplification of the whole BCRP sequence. 
CDS4 indicates that four samples of amplified BCRP were produced using of hABCG2 v5r 2 
reverse primer at temperatures specified previously, as a result leading to production BCRP 
cDNA which was of 24 nucleotides shorter. 
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11. Discussion: 
Goal of this study was to prepare a universal plasmid (pZSV5, pLNCXV5) which 
contains a short sequence of V5 tag. This plasmid enables further cloning of coding sequences of 
selected efflux transporters so that the V5 tag is localized on their 3’-end. Once constructed, the 
plasmid can be further used to transfect the desired cell line, thus developing an in vitro cell 
model. Since the transporter is produced as a fusion protein with the V5 tag localized on their C-
end, the tag could be used as a universal marker of the transporter expression detectable by 
immunoanalytical methods (e.g. Western blot analysis). 
 The study begun with the development of the artificial V5 tag DNA. Different 
oligonucleotides, their starting concentrations and temperature profiles were employed in order 
to get the desired V5 tag by employing two different approaches for V5 tag assembly. One 
including the hybridization of two pairs of complementary oligonucleotides and their subsequent 
ligation, the other based on simple hybridization of the whole sequence from two complementary 
oligonucleotides. Both approaches proved to be suitable for V5 tag assembly. The success of 
hybridization and ligation in both was greatly affected by starting concentrations of 
oligonucleotides. Low concentrations resulted in an unclear band with lots of impurities forming 
a smear. In contrast, the use of high oligonucleotides concentrations resulted in clear band 
indicating successful preparation of the V5 tag. Furthermore, temperature profile of 
oligonucleotide hybridization of complimentary pairs were successful only when heated at three 
different temperatures; 90°C, 70°C and 37°C during the hybridization. On the contrary, 
hybridization of two complimentary oligonucleotide sequences forming the V5 tag sequence 
were successful at temperature profile of 95°C.  
With a successful preparation of the V5 tag, the experiment was proceeded with the next 
step, which was the linearization of pZeoSV2(-) and pLNCX2 plasmids using the XhoI and NotI 
restriction endonucleases, preparing the plasmids to be ligated with the V5 tag. The attempt 
resulted in a successful identification and isolation of the linearized plasmids, which was 
followed by the ligation with the V5 tag. In order to optimize the ligation process. 
 Different ratios of the insert and plasmid were tested. Ratio 1:3 appeared to be the most 
optimal since it resulted in the most developed colonies, and also the individual colonies were 
evenly spaced out on the dish making the isolation possible without the chance of cross 
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contamination with the surrounding colonies. Nonetheless, all attempts made were 
unsuccessfully in creating the new pZSV5 plasmid. However, in case of pLNCXV5 the insertion 
of the V5 tag appeared to be successful. Then again the verification of the resulting plasmid was 
based only on the results from restriction analysis and further sequencing will be necessary to 
confirm the actual sequence of the pLNCXV5 plasmid. Only after this the plasmid could be used 
for cloning of BCRP and other efflux transporters and their subsequent expression in mammalian 
cells. 
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